Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021105 | 0.95 | L3MBTL1 (0.38) | TSHRL3MBTL1ESR1ESR2NPC1 | |
| SCHEMBL18660420 | 0.84 | ALDH1A1 (0.40) | ESR2MAPTCNR2KIF11 | |
| SCHEMBL13232168 | 0.83 | CYP2D6 (0.39) | L3MBTL1ESR1ESR2NPC1RAB9A | |
| SCHEMBL317837 | 0.82 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL14865568 | 0.79 | TSHR (0.39) | TSHRL3MBTL1ESR1ESR2NPC1 | |
| SCHEMBL18660141 | 0.79 | CSNK1E (0.44) | CNR2 | |
| SCHEMBL13232167 | 0.78 | EPHX1 (0.38) | L3MBTL1NPC1RAB9ACNR2CNR1 | |
| SCHEMBL317660 | 0.77 | GPR84 (0.35) | MAPT | |
| SCHEMBL13693153 | 0.77 | KIF11 (0.35) | KIF11 | |
| SCHEMBL11859819 | 0.74 | TSHR (0.41) | TSHRNPC1MAPTRAB9AKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8278347-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8263593-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8124648-B2 | Therapeutic lactams | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7482475-B2 | Therapeutic lactams | ALLERGAN, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7439372-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | OLD DAVID W | 2008-03-06 | — | — | US | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | TSHR 4505/4885L3MBTL1 4407/4885ESR1 4028/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | TSHR 2567/4885L3MBTL1 3994/4885ESR1 2855/4885 |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | TSHR 4505/4885L3MBTL1 4407/4885ESR1 4028/4885 |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | TSHR 4382/4885L3MBTL1 4299/4885ESR1 2259/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | TSHR 1819/4885L3MBTL1 4740/4885ESR1 2491/4885 |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | TSHR 562/4885L3MBTL1 4593/4885ESR1 2727/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | TSHR 4382/4885L3MBTL1 4299/4885ESR1 2259/4885 |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | TSHR 387/4885L3MBTL1 4531/4885ESR1 3268/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | TSHR 3467/4885L3MBTL1 3886/4885ESR1 3043/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | TSHR 2567/4885L3MBTL1 3994/4885ESR1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.